Search

Your search keyword '"Raghunathan, Rohit R"' showing total 15 results
Start Over Author "Raghunathan, Rohit R"
15 results on '"Raghunathan, Rohit R"'

5. Optimizing the implementation of systematic financial screening.

Author

Beauchemin, Melissa Parsons, primary, DeStephano, David, additional, Raghunathan, Rohit R., additional, Accordino, Melissa Kate, additional, Hillyer, Grace C., additional, Kahn, Justine, additional, Law, Cynthia, additional, Harden, Erik, additional, Wright, Jason Dennis, additional, Kukafka, Rita, additional, and Hershman, Dawn L., additional

Published
2022
Full Text
View/download PDF

9. Impact of a hospital specialty pharmacy in partnership with a free-standing care coordination organization on time to delivery and receipt of oral anticancer drugs.

Author

Beauchemin, Melissa Parsons, primary, Lichtenstein, Morgan RL, additional, Raghunathan, Rohit R., additional, Doshi, Sahil D, additional, Law, Cynthia, additional, Accordino, Melissa Kate, additional, Elkin, Elena B., additional, Wright, Jason Dennis, additional, and Hershman, Dawn L., additional

Published
2021
Full Text
View/download PDF

11. Factors associated with failure to receive oral anticancer drugs.

Author

Doshi, Sahil D, primary, Lichtenstein, Morgan RL, additional, Beauchemin, Melissa Parsons, additional, Raghunathan, Rohit R., additional, Law, Cynthia, additional, Accordino, Melissa Kate, additional, Wright, Jason Dennis, additional, Elkin, Elena B., additional, and Hershman, Dawn L., additional

Published
2021
Full Text
View/download PDF

15. New and Persistent Sedative-Hypnotic Use After Adjuvant Chemotherapy for Breast Cancer.

Author

Cogan JC, Raghunathan RR, Beauchemin MP, Accordino MK, Huang Y, Elkin EB, Melamed A, Wright JD, and Hershman DL

Subjects
Humans, Aged, United States epidemiology, Female, Drug Prescriptions, Medicare, Hypnotics and Sedatives adverse effects, Benzodiazepines adverse effects, Chemotherapy, Adjuvant adverse effects, Breast Neoplasms drug therapy, Breast Neoplasms chemically induced
Abstract

Background: Sedative-hypnotic medications are used to treat chemotherapy-related nausea, anxiety, and insomnia. However, prolonged sedative-hypnotic use can lead to dependence, misuse, and increased health-care use. We aimed to estimate the rates at which patients who receive adjuvant chemotherapy for breast cancer become new persistent users of sedative-hypnotic medications, specifically benzodiazepines and nonbenzodiazepine sedative-hypnotics (Z-drugs)., Methods: Using the MarketScan health-care claims database, we identified sedative-hypnotic-naïve patients who received adjuvant chemotherapy for breast cancer. Patients who filled 1 and more prescriptions during chemotherapy and 2 and more prescriptions up to 1 year after chemotherapy were classified as new persistent users. Univariate and multivariable logistic regression analyses were used to estimate odds of new persistent use and associated characteristics., Results: We identified 22 039 benzodiazepine-naïve patients and 23 816 Z-drug-naïve patients who received adjuvant chemotherapy from 2008 to 2017. Among benzodiazepine-naïve patients, 6159 (27.9%) filled 1 and more benzodiazepine prescriptions during chemotherapy, and 963 of those (15.6%) went on to become new persistent users. Among Z-drug-naïve patients, 1769 (7.4%) filled 1 and more prescriptions during chemotherapy, and 483 (27.3%) became new persistent users. In both groups, shorter durations of chemotherapy and receipt of opioid prescriptions were associated with new persistent use. Medicaid insurance was associated with new persistent benzodiazepine use (odds ratio = 1.88, 95% confidence interval = 1.43 to 2.47) compared with commercial or Medicare insurance., Conclusions: Patients who receive sedative-hypnotic medications during adjuvant chemotherapy for breast cancer are at risk of becoming new persistent users of these medications after chemotherapy. Providers should ensure appropriate sedative-hypnotic use through tapering dosages and encouraging nonpharmacologic strategies when appropriate., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results